Talzenna (talazoparib capsules and liquid-filled soft gelatin capsules) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has metastatic castration-resistant prostate cancer
• Patient meets ONE of the following (i or ii): i. The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog; OR ii. Patient has had a bilateral orchiectomy
• Patient has homologous recombination repair (HRR) gene-mutated disease
• The medication is used in combination with Xtandi (enzalutamide capsules and tablets)

Approval duration

1 year